A new study shows that multiple sclerosis patients with HHV-6 have higher risk of relapse and poor response to IFN-beta treatment.
The trigger for neurological disease in a subset of patients with MS?
The administration of immune agents to patients (known as Interferon-Beta-1b, or IFN-beta, therapy) has been widely used in the treatment and maintenance of multiple sclerosis (MS). Additionally, it is known that the risk of MS exacerbation is much higher in patients with active HHV-6 infection than in patients with a latent infection of the virus (Lafuente 2006, 2007; Chapenko 2003). In this new study from Madrid, researchers examined the effectiveness of IFN-1b therapy in multiple sclerosis patients with active HHV-6 infection. By monitoring the HHV-6 DNA levels of MS patients undergoing IFN-beta therapy, investigators were able to find that patients with active HHV-6 infection had a higher risk of severe MS relapse and poor response to IFN-beta therapy than patients …
- Page 2 of 2